Psilocybin Trial Targets Fear of Cancer Recurrence After Early Breast Cancer Treatment
A phase 2 trial at NYU Langone Health will test whether psilocybin-assisted psychotherapy can ease fear of cancer recurrence in women treated for early-stage breast cancer. The study is designed for a problem that sits outside the usual oncology toolkit: persistent worry that the disease will return, even after successful treatment and remission.
The trial plans to enroll 100 outpatients with stage 1 or 2 ER/PR-positive, HER2-negative breast cancer who have already completed initial therapy and remain at least one year beyond that treatment milestone. Participants must also have clinically significant fear of cancer recurrence, defined by a Fear of Cancer Recurrence Inventory-Short Form score above 20 at screening. Researchers will compare a single 25 mg oral dose of psilocybin against a 5 mg oral dose used as an active placebo, with both doses delivered alongside a psychotherapy platform.
The study’s central question is not whether psilocybin changes tumor biology. It is whether a carefully structured psychedelic experience can interrupt the cognitive loop of recurrence anxiety, depressive symptoms, and diminished quality of life that often persist long after the last infusion, operation, or radiation session ends.
Why Fear of Recurrence Becomes a Chronic Symptom
For many survivors, the end of active treatment does not end distress. A normal follow-up scan or reassuring oncology visit can bring only temporary relief before the same intrusive cycle returns: pain is interpreted as progression, fatigue is read as relapse, and every surveillance appointment becomes a source of anticipatory dread. In that setting, fear of cancer recurrence behaves less like a fleeting emotion and more like a clinically meaningful syndrome that can erode daily functioning.
This trial is built around that reality. By pairing psilocybin with psychotherapy, investigators are testing whether a psychedelic-assisted model can produce durable shifts in emotional processing, not merely transient mood elevation. The biological plausibility rests on the drug’s ability to alter rigid patterns of attention and self-referential thinking, a mechanism that may matter when patients are trapped in repetitive, threat-focused thinking about recurrence and mortality.
One dose, one session, and an eight-hour observation window may still leave an enduring imprint on anxiety circuitry.
How the Study Is Structured
The design is a double-blind, parallel-assignment randomized controlled trial with two arms. One group receives 25 mg psilocybin, and the other receives 5 mg psilocybin as an active comparator dose. Both medication sessions are expected to last about eight hours, a duration that reflects the intensive clinical oversight typically required during psychedelic administration.
Masking includes both participants and investigators. The structure is important because subjective drug effects can make blinding difficult, especially in trials involving psychedelics. Using a low-dose comparator instead of inert placebo may help preserve expectancy balance, although the extent to which that strategy fully prevents unblinding will remain a practical issue for interpretation.
The primary endpoint is the Fear of Cancer Recurrence Inventory-Short Form, a 9-item self-report scale scored from 0 to 36, with higher scores indicating more severe fear of recurrence. Assessment is scheduled at baseline and again four weeks after the dose session. That endpoint is well matched to the clinical problem: the study is not chasing acute intoxication effects, but whether post-session change in worry persists beyond the immediate psychedelic experience.
Psychiatric Outcomes Sit Beside Quality of Life Measures
Secondary outcomes extend beyond recurrence fear alone. Investigators will track clinician-rated change in severity using the Clinical Global Impression-Severity scale and Clinical Global Impression-Improvement scale. They will also measure anxiety and depression with the Hospital Anxiety and Depression Scale, quality of life with the Functional Assessment of Cancer Therapy-Breast, and spiritual well-being with the FACIT-Sp-12.
That mix of endpoints reflects the clinical burden carried by cancer survivors who are not necessarily medically ill in the acute sense, yet remain psychologically strained. Anxiety and depression often cluster with fear of recurrence, and quality-of-life impairment can extend into relationships, sleep, concentration, and the willingness to re-engage with ordinary life. Spiritual well-being, while sometimes overlooked in oncology trials, may prove relevant when the therapy is intended to shift existential distress rather than only reduce symptom scores.
A therapy that changes one domain while leaving the others untouched would be only a partial answer.
Eligibility Criteria Define a Narrow and Safety-Focused Population
The inclusion criteria are tightly drawn. Participants must be women aged 21 or older with early-stage hormone receptor-positive, HER2-negative breast cancer, and they must have completed initial treatment. Ongoing adjuvant endocrine therapy, and/or HER2 therapy, is allowed. Each participant must also have an identified support person and agree to be accompanied home after dosing.
Those safeguards are more than administrative details. Psilocybin can produce intense perceptual and emotional changes, and the study excludes anyone with unstable medical illness, significant laboratory or ECG abnormalities, psychotic disorders, serious bipolar-spectrum family history in a first-degree relative, clinically significant suicidality, hallucinogen persisting perception disorder, pregnancy, or lactation. Screening also excludes patients with blood pressure above 160/100 or heart rate above 110 bpm at screening, baseline, or immediately before dosing, a practical effort to avoid hypertensive crisis in a setting where sympathetic activation could be hazardous.
The psychiatric exclusions matter because psychedelic-assisted therapy is being tested here as a controlled intervention, not as a general wellness strategy. The trial is intentionally conservative about who can safely undergo it.
Why the Comparator Dose Matters
The 5 mg dose serves as an active placebo, not a fully inert control. In psychedelic studies, expectancy can strongly influence patient-reported outcomes, particularly when the intervention includes psychotherapy and a prolonged, highly supervised dosing session. A low-dose comparator may preserve some of the sensory and psychological cues of treatment while reducing the likelihood of a full psychedelic effect, making the comparison more informative than an ordinary placebo design would be.
Still, the blinding challenge remains real. Participants may infer assignment from the intensity of their experience, and that could shape self-reported fear, anxiety, and quality-of-life scores. The trial’s interpretation will therefore depend not only on outcome differences, but on whether the active comparator can adequately separate pharmacology from expectation and therapeutic ritual.
The Oncology Question Behind the Psychedelic Signal
Cancer medicine has become increasingly effective at prolonging survival, especially in hormone receptor-positive early breast cancer. The emotional aftermath of that success has become harder to ignore. Patients often leave treatment with a survivor identity that is fragile, hypervigilant, and chronically alarmed. If psilocybin-assisted psychotherapy can reliably reduce fear of recurrence in this population, the result would point toward a new model for treating cancer-related distress: one that reaches beyond symptom suppression and into the cognitive architecture of fear.
The study is sponsored by NYU Langone Health with collaboration from the National Cancer Institute, and the estimated study period stretches from 2027 through 2031. Results are not yet available, which leaves the key questions open: whether the effect will be large enough to matter in day-to-day survivorship care, whether it will persist beyond the four-week assessment window, and whether the psychotherapy platform is doing as much work as the drug itself.
Those answers will determine whether this approach becomes a serious survivorship intervention or remains a carefully watched experiment in psycho-oncology.